{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-067928","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.939126+00:00","generated_at":"2026-06-27T01:09:13.353842+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Jeffrey K. Tong to resign from Nurix board, effective at 2022 annual meeting","bullets":["Jeffrey K. Tong, Ph.D., will resign as Class II director and from Audit and Compensation Committees.","Resignation effective as of date of 2022 Annual Meeting of Stockholders.","Resignation not due to any disagreement with the Company on operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-067928","json":"https://secwatch.observer/filing/0001193125-22-067928.json","markdown":"https://secwatch.observer/filing/0001193125-22-067928.md","text":"https://secwatch.observer/filing/0001193125-22-067928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522067928/0001193125-22-067928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522067928/d324477d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:09:13.353842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1a56310f5","claim":"Jeffrey K. Tong resigned as Class II Director at Nurix Therapeutics, Inc..","evidence_excerpt":"On March 2, 2022, Jeffrey K. Tong, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that he will resign as a Class II member of the Board and as a member of the Board’s Audit Committee and Compensation Committee, effective on the date of the Company’s 2022 Annual Meeting of Stockholders (the “Resignation”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522067928/0001193125-22-067928-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}